Nov 12 (Reuters) - Novavax (NVAX.O), opens new tab cut its annual revenue forecast on Tuesday, citing lower-than-expected ...

Novavax has made a smaller splash in the U.S. Covid-19 vaccine market than it had hoped. But it's betting on licensing deals ...

Novavax has received the green light from the US Food and Drug Administration (FDA) to resume clinical trials for its ...

Novavax, Inc., based in Gaithersburg, Maryland, is a global biotechnology company focused on developing and commercializing innovative protein-based vaccines to combat serious infectious diseases, ...

Novavax has inked another settlement for a past COVID-19 vaccine supply deal. | Novavax has inked another settlement for a ...

Shares in Novavax fell by as much as one-fifth Wednesday morning after the company disclosed the Food and Drug Administration halted clinical testing of its combination vaccine for COVID-19 and ...

We gleaned this information from our observations today when Benzinga's options scanner highlighted 9 extraordinary options activities for Novavax. This level of activity is out of the ordinary.

Novavax has been gearing up to launch a phase 3 trial of what may result in an important product: A combined flu and coronavirus vaccine. But the company now faces a roadblock, saying regulators ...

Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced that the U.S. Food and Drug Administration (FDA) has removed the ...

Shares of Novavax NVAX lost nearly 20% on Wednesday after the company announced that the FDA has placed a clinical hold on its experimental COVID-19-Influenza Combination (“CIC”) and stand ...

Novavax reports Q3 2024 sales of $84.5 million, beating estimates, with a net loss of $121 million. EPS improves, FDA approves new vaccine, and revenue guidance is lowered. Vandana Singh FDA Gives ...

Novavax, Inc. ( NASDAQ: NVAX) Q3 2024 Earnings Conference Call November 12, 2024 8:30 AM ET ...